Radafaxine (developmental code GW-353,162; also known as (2S,3S)-hydroxybupropion or (S,S)-hydroxybupropion[1]) is a norepinephrine–dopamine reuptake inhibitor (NDRI) which was under development by GlaxoSmithKline in the 2000s for a variety of different indications but was never marketed.

[2] Regulatory filing was planned for 2007,[3] but development was discontinued in 2006 due to "poor test results".

[5][6] This, according to GlaxoSmithKline, may account for the increased effect of radafaxine on pain and fatigue.

[7] At least one study suggests that radafaxine has a low abuse potential similar to bupropion.

[10][11][12] Manifaxine (GW-320,659) was developed as an analogue of radafaxine and has been studied for the treatment of ADHD and obesity.